JLM-BIOCITY Pharma Startup Pitch Evening

Date: 26.02.2017 |

JLM-BIOCITY presents: 

JLM-BIOCITY      P h a r m a      S t a r t u p     P i t c h      Evening

Thursday, April 20th, 2017

JLM-BioCity is looking for GREAT  Pharma Start-ups to pitch to a panel of the  following leading pharma investors:

Prof David Sidransky MD, co-Founder & General Partner, Israel Biotech Fund

• to be determined - Managing Director, OrbiMed

• Steven Tepper -Israel Brokerage & Investments – IBI

If you are interested, contact Dr Vitali Shilo at  vitali.shilo@gmail.com

JBNF-Biomed is launching a series of startup pitch evenings, to be held every three months, alternatively in Biomed or in Pharma. The next startup pitch evening will be for Pharma startups. 

The purpose of these events is to give a platform for promising life science start-ups to present themselves to a forum of investors. In addition, it will help other bio-entrepreneurs to learn how to better pitch their start-ups and to acquaint themselves with investors. JBNF-Biomed is already looking for Biomed startups as well as panelists for its next Biomed startup Pitch Evening scheduled for June.

JLM-BioCity (JBNF-BioMed) is delighted to announce this event is sponsored by Azrieli College of Engineering and AtoBe – Azrieli College of Engineering Startup Enterpreneurship Center

The presentations will all be given in English.

RVSP to reserve your place. There will be a 20 NIS entrance fee to the event.


LOCATION: Auditorium 001, on the first floor (using , in the old building 4. 

About our panelists:

Prof David Sidransky MD, Co-Founder and General Partner of Israel Biotech Fund

Co-Founder and General Partner of Israel Biotech Fund. Dr. Sidransky is a renowned oncologist, research scientist and Professor of Oncology and Cellular & Molecular Medicine at John Hopkins University and Hospital. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: OMED), a genetic testing company that was sold to Gene Logic in 1998, and Response Genetics (NASDAQ: RGDX), a developer of markers for cancer therapy. 

to be determined, OrbiMed

Dr Steven Tepper -Senior Research Analyst for Pharmaceuticals and Biotechnology. Israel Brokerage & Investments (IBI Investment House)

Dr Steven Tepper IBI  is a leading sell-side equity analyst in the pharma and biomed space in Israel, as acknowledged by institutional clients, the financial media and the managements of publicly traded healthcare companies in Israel. Activities included publishing initial research reports, maintaining ongoing company coverage, producing periodical sector updates, marketing investment ideas and managing unique valuation models, built upon the characteristics of the biopharma industry.

Comments are closed.